Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma

被引：2
|
作者：
Smalley, Keiran S. M. [1 ,2 ]
Fedorenko, Inna V. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL 33607 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL 33607 USA
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2015年 / 2卷 / 04期
基金：
美国国家卫生研究院;
关键词：
BRAF; ephrin; melanoma; metastasis; resistance;
D O I：
10.1080/23723556.2015.1008291
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independent erythropoietin-producing hepatocellular receptor A2 (EphA2) signaling.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
    Queirolo, Paola
    Picasso, Virginia
    Spagnolo, Francesco
    [J]. CANCER TREATMENT REVIEWS, 2015, 41 (06) : 519 - 526
  • [2] BRAF and MEK inhibition in melanoma
    Dossett, Lesly A.
    Kudchadkar, Ragini R.
    Zager, Jonathan S.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) : 559 - 570
  • [3] Inhibition of BRAF and MEK in BRAF-mutant melanoma
    Smalley, Keiran S. M.
    Sondak, Vernon K.
    [J]. LANCET, 2015, 386 (9992): : 410 - 412
  • [4] COMBINED BRAF AND MEK INHIBITION IMPROVES OUTCOME IN METASTATIC MELANOMA
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (11) : 971 - 971
  • [5] Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
    Long, G. V.
    Stroyakovskiy, D.
    Gogas, H.
    Levchenko, E.
    de Braud, F.
    Larkin, J.
    Garbe, C.
    Jouary, T.
    Hauschild, A.
    Grob, J. J.
    Sileni, V. Chiarion
    Lebbe, C.
    Mandala, M.
    Millward, M.
    Arance, A.
    Bondarenko, I.
    Haanen, J. B. A. G.
    Hansson, J.
    Utikal, J.
    Ferraresi, V.
    Kovalenko, N.
    Mohr, P.
    Probachai, V.
    Schadendorf, D.
    Nathan, P.
    Robert, C.
    Ribas, A.
    DeMarini, D. J.
    Irani, J. G.
    Casey, M.
    Ouellet, D.
    Martin, A. -M.
    Le, N.
    Patel, K.
    Flaherty, K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20): : 1877 - 1888
  • [6] BRAF/MEK inhibition in melanoma patients with rare BRAF mutations
    Hassel, Jessica Cecile
    Menzer, Christian
    Menzies, Alexander M.
    Carlino, Matteo S.
    Long, Georgina V.
    Kefford, Richard
    Eigentler, Thomas K.
    Johnson, Douglas Buckner
    Schlaak, Max
    Meiss, Frank
    Schilling, Bastian
    Gutzmer, Ralf
    Pfoehler, Claudia
    Meier, Friedegund Elke
    Zimmer, Lisa
    Haalck, Thomas
    Thoms, Kai
    Kopp-Schneider, Annette
    Enk, Alexander
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
    Richman, Juliet
    Martin-Liberal, Juan
    Diem, Stefan
    Larkin, James
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (09) : 1285 - 1297
  • [8] BRAF Inhibition for metastatic Melanoma
    Hauschild, A.
    [J]. HNO, 2019, 67 (04) : 238 - 238
  • [9] Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
    Welsh, Sarah J.
    Rizos, Helen
    Scolyer, Richard A.
    Long, Georgina V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 62 : 76 - 85
  • [10] Outcomes following progression on BRAF/MEK inhibition in metastatic melanoma.
    Mason, Robert
    Heng, Sharon
    Atkinson, Victoria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345